<p>约翰逊投资顾问公司在最新的 13F 文件中披露，第三季度将其在 Zimmer Biomet Holdings, Inc.（纽约证券交易所代码：ZBH - 免费报告）的持仓减少了 38.3%。该公司在此期间出售了 17,924 股后，持有 28,930 股该医疗设备提供商的股票。约翰逊投资顾问公司在 Zimmer Biomet 的持股在最近一个季度末价值 285 万美元。</p>
<p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
<ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
<p>其他机构投资者和对冲基金也买卖了该公司的股票。Key Financial Inc 在第三季度将其在 Zimmer Biomet 的股份增加了 164.6%。Key Financial Inc 现在拥有 262 股该医疗设备提供商的股票，价值 26,000 美元，此前在此期间又收购了 163 股。Cullen Frost Bankers Inc.在第三季度将其在 Zimmer Biomet 的股份增加了 66.7%。Cullen Frost Bankers Inc.现在拥有 290 股该医疗设备提供商的股票，价值 29,000 美元，此前在此期间又购买了 116 股。Root Financial Partners LLC 在第三季度购买了 Zimmer Biomet 的新头寸，价值约 31,000 美元。Cary Street Partners Investment Advisory LLC 在第二季度将其在 Zimmer Biomet 的股份增加了 83.7%。Cary Street Partners Investment Advisory LLC 现在拥有 327 股该医疗设备提供商的股票，价值 30,000 美元，此前在此期间又购买了 149 股。最后，Mather Group LLC 在第三季度购买了 Zimmer Biomet 的新股份，价值约 36,000 美元。88.89% 的股票由机构投资者持有。</p>
<h2>分析师升级与降级</h2>
<p>几位股票分析师最近对 ZBH 股票发表了评论。富国银行将 Zimmer Biomet 的目标价格从 93.00 美元上调至 98.00 美元，并在周三的报告中给予该股票 “持平” 评级。瑞银集团重申了 “卖出” 评级，并在周三的报告中对 Zimmer Biomet 的股票设定了 89.00 美元的目标价格。BTIG 研究在周二的研究报告中重申了 “买入” 评级，并对 Zimmer Biomet 的股票设定了 112.00 美元的目标价格。Sanford C. Bernstein 在 1 月 9 日的报告中将 Zimmer Biomet 的目标价格从 97.00 美元上调至 99.00 美元，并给予该公司 “市场表现” 评级。最后，约翰逊·赖斯在 11 月 5 日的报告中对 Zimmer Biomet 设定了 112.00 美元的目标价格。一位分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 106.45 美元。</p>
<ul>
<li>直觉外科在机器人手术创新中领先</li>
</ul>
<p><strong>查看我们关于 Zimmer Biomet 的最新股票报告</strong></p>
<h2>Zimmer Biomet 新闻摘要</h2>
<p>以下是本周影响 Zimmer Biomet 的主要新闻：</p>
<ul>
<li>积极情绪：第四季度超预期——ZBH 报告每股收益为 2.42 美元，收入约为 22.4 亿美元（同比增长约 10.9%），超出市场预期，得益于对髋关节和膝关节设备的强劲需求。路透社：Zimmer Biomet 超出季度预期</li>
<li>积极情绪：新回购计划宣布——管理层在业绩公布时推出了一项新的回购计划，支持股价并传达了对现金生成的信心。雅虎财经：ZBH 在业绩超预期和回购后上涨</li>
<li>积极情绪：指数/行业提升——业绩超预期促进了更广泛的医疗行业指数流动，并被认为提升了罗素 1000 医疗行业的情绪。指数/行业认可可以放大对该股票的需求。Kalkine：超出预期，提升罗素 1000 医疗</li>
<li>积极情绪：分析师动态——几家机构调整了目标或重申了评级（花旗和富国银行将目标价格上调至 98 美元；BTIG 重申 112 美元的买入目标），为短期提供了一些支持。Benzinga：分析师更新</li>
<li>中性情绪：指导方针保守但大致符合——2026 财年每股收益指导设定在 8.30–8.45 美元，收入指导在 84 亿–86 亿美元，基本符合市场预期，但用谨慎的语言强调了限制上行预期的因素。MSN：第四季度超出预期，但对 2026 年的指导持谨慎态度</li>
<li>中性情绪：美国销售团队重组——管理层指出美国销售团队的重组和过渡，预计将改善长期执行，但增加了短期不确定性，并在电话会议上传达了谨慎的语气。雅虎财经：第四季度深度分析——销售团队重组</li>
<li>消极情绪：利润率和阻力——管理层承认利润率压力（本季度出现了一些收缩），并指出关税和成本动态可能对 2026 年的利润扩张造成拖累。这些因素可能限制盈利能力的上行。Zacks：第四季度收益与利润率评论</li>
<li>消极情绪：管理层语气谨慎——尽管业绩超出预期，但谨慎的指导和评论暗示短期内上行空间有限，并在过渡期间增加了执行风险，这可能限制市盈率的扩张。MSN：第四季度收益电话会议记录</li>
</ul>
<h2>Zimmer Biomet 价格表现</h2>
<ul>
<li>2 家机器人手术公司挑战直觉外科的领先地位</li>
</ul>
<p>ZBH 股票周四开盘价为 95.51 美元。Zimmer Biomet Holdings, Inc.的 52 周低点为 84.59 美元，52 周高点为 114.44 美元。该公司的市值为 189.3 亿美元，市盈率为 26.98，市盈率增长比为 2.34，贝塔值为 0.62。该公司的 50 日简单移动平均为 90.01 美元，200 日简单移动平均为 95.64 美元。该公司的速动比率为 1.39，流动比率为 1.98，债务与股本比率为 0.55。</p>
<p>Zimmer Biomet (NYSE:ZBH - 获取免费报告) 最近一次公布财报是在 2 月 10 日，星期二。这家医疗设备供应商报告了每股收益（EPS）为 2.42 美元，超出市场普遍预期的 2.38 美元，超出幅度为 0.04 美元。Zimmer Biomet 的净利润率为 8.56%，股本回报率为 12.93%。该公司本季度的收入为 22.4 亿美元，而分析师预期为 22.2 亿美元。在去年同期，该公司的每股收益为 2.31 美元。与去年同期相比，公司的收入增长了 10.9%。Zimmer Biomet 将其 2026 财年的指引设定为每股收益在 8.300 到 8.450 之间。分析师预计，Zimmer Biomet Holdings, Inc. 在当前财年将公布每股收益为 8.22 美元。</p>
<h2>Zimmer Biomet 宣布分红</h2>
<p>该公司最近还披露了季度分红，分红于 1 月 30 日，星期五支付。12 月 30 日的股东获得了 0.24 美元的分红。这相当于年化分红为 0.96 美元，分红收益率为 1.0%。该分红的除息日为 12 月 30 日。Zimmer Biomet 的分红支付比率（DPR）目前为 27.12%。</p>
<h2>Zimmer Biomet 公司简介</h2>
<p>（免费报告）</p>
<p>Zimmer Biomet NYSE: ZBH 是一家全球医疗设备公司，专注于肌肉骨骼健康护理。公司总部位于印第安纳州的华沙，设计、制造和销售广泛的产品组合，用于治疗关节疾病、骨骼疾病及相关病症。其客户包括依赖于植入物、仪器和相关服务进行重建和修复手术的骨科和牙科外科医生、医院、门诊手术中心及其他医疗服务提供者。</p>
<p>公司的产品涵盖髋关节、膝关节和肩关节的关节置换系统；创伤和四肢植入物；脊柱和胸部解决方案；牙科和颅面植入物及假体；以及运动医学设备。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Zimmer Biomet</li>
<li>这是下一个大钱潮吗？</li>
<li>华尔街传奇在镜头前命名 2026 年第一只股票</li>
<li>ISPC：从小型股到生命科学市场颠覆者！</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>埃隆是否在为银色冲击做准备？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Zimmer Biomet 吗？</h2>
<p>在你考虑 Zimmer Biomet 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Zimmer Biomet 并不在名单上。</p>
<p>虽然 Zimmer Biomet 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

医药突破 ETF - ALPS

<p>Johnson Investment Counsel Inc. 在第三季度减少了对 Zimmer Biomet Holdings, Inc. 的持股比例，下降了 38.3%，目前持有 28,930 股，价值 285 万美元。其他机构投资者也调整了他们的持仓，Key Financial Inc. 的持股增加了 164.6%。分析师对 Zimmer Biomet 的评级不一，目标价格范围在 89 美元到 112 美元之间。该股票的平均评级为 “持有”，共识价格目标为 106.45 美元。最近的财报超出预期，但由于潜在的利润压力和重组努力，前景依然谨慎</p>

<p>Johnson Investment Counsel Inc. lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 38.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 28,930 shares of the medical equipment provider's stock after selling 17,924 shares during the period. Johnson Investment Counsel Inc.'s holdings in Zimmer Biomet were worth $2,850,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>约翰逊投资顾问公司在最新的 13F 文件中披露，第三季度将其在 Zimmer Biomet Holdings, Inc.（纽约证券交易所代码：ZBH - 免费报告）的持仓减少了 38.3%。该公司在此期间出售了 17,924 股后，持有 28,930 股该医疗设备提供商的股票。约翰逊投资顾问公司在 Zimmer Biomet 的持股在最近一个季度末价值 285 万美元。</p>
</div><p>Get <strong>Zimmer Biomet</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Zimmer Biomet</strong> 警报：</p>
</div><ul>
<li>A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH</li>
</ul>
<div class="lb-trans"><ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
</div><p>Other institutional investors and hedge funds have also bought and sold shares of the company. Key Financial Inc boosted its stake in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 116 shares during the period. Root Financial Partners LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC boosted its stake in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 149 shares during the period. Finally, Mather Group LLC. purchased a new stake in Zimmer Biomet during the 3rd quarter valued at approximately $36,000. 88.89% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也买卖了该公司的股票。Key Financial Inc 在第三季度将其在 Zimmer Biomet 的股份增加了 164.6%。Key Financial Inc 现在拥有 262 股该医疗设备提供商的股票，价值 26,000 美元，此前在此期间又收购了 163 股。Cullen Frost Bankers Inc.在第三季度将其在 Zimmer Biomet 的股份增加了 66.7%。Cullen Frost Bankers Inc.现在拥有 290 股该医疗设备提供商的股票，价值 29,000 美元，此前在此期间又购买了 116 股。Root Financial Partners LLC 在第三季度购买了 Zimmer Biomet 的新头寸，价值约 31,000 美元。Cary Street Partners Investment Advisory LLC 在第二季度将其在 Zimmer Biomet 的股份增加了 83.7%。Cary Street Partners Investment Advisory LLC 现在拥有 327 股该医疗设备提供商的股票，价值 30,000 美元，此前在此期间又购买了 149 股。最后，Mather Group LLC 在第三季度购买了 Zimmer Biomet 的新股份，价值约 36,000 美元。88.89% 的股票由机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级与降级</h2>
</div><p>Several equities analysts have recently commented on ZBH shares. Wells Fargo &amp; Company boosted their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday. UBS Group reiterated a &#34;sell&#34; rating and issued a $89.00 price target on shares of Zimmer Biomet in a report on Wednesday. BTIG Research reiterated a &#34;buy&#34; rating and issued a $112.00 price target on shares of Zimmer Biomet in a research note on Tuesday. Sanford C. Bernstein increased their price objective on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a &#34;market perform&#34; rating in a report on Friday, January 9th. Finally, Johnson Rice set a $112.00 target price on Zimmer Biomet in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $106.45.</p>
<div class="lb-trans"><p>几位股票分析师最近对 ZBH 股票发表了评论。富国银行将 Zimmer Biomet 的目标价格从 93.00 美元上调至 98.00 美元，并在周三的报告中给予该股票 “持平” 评级。瑞银集团重申了 “卖出” 评级，并在周三的报告中对 Zimmer Biomet 的股票设定了 89.00 美元的目标价格。BTIG 研究在周二的研究报告中重申了 “买入” 评级，并对 Zimmer Biomet 的股票设定了 112.00 美元的目标价格。Sanford C. Bernstein 在 1 月 9 日的报告中将 Zimmer Biomet 的目标价格从 97.00 美元上调至 99.00 美元，并给予该公司 “市场表现” 评级。最后，约翰逊·赖斯在 11 月 5 日的报告中对 Zimmer Biomet 设定了 112.00 美元的目标价格。一位分析师给予该股票 “强烈买入” 评级，八位分析师给予 “买入” 评级，九位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价格为 106.45 美元。</p>
</div><ul>
<li>Intuitive Surgical Leads the Pack in Robotic Surgery Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>直觉外科在机器人手术创新中领先</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on Zimmer Biomet</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Zimmer Biomet 的最新股票报告</strong></p>
</div><h2>Zimmer Biomet News Summary</h2>
<div class="lb-trans"><h2>Zimmer Biomet 新闻摘要</h2>
</div><p>Here are the key news stories impacting Zimmer Biomet this week:</p>
<div class="lb-trans"><p>以下是本周影响 Zimmer Biomet 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Q4 beat — ZBH reported EPS of $2.42 and revenue of ~$2.24B (up ~10.9% YoY), beating consensus and driven by strong demand for hip and knee devices. Reuters: Zimmer Biomet beats quarterly estimates</li>
<li>Positive Sentiment: New buyback announced — Management unveiled a fresh repurchase program alongside the results, which supports the share price and signals confidence in cash generation. Yahoo Finance: ZBH up after earnings beat and buyback</li>
<li>Positive Sentiment: Index/sector lift — The earnings beat contributed to broader healthcare index flows and was noted as lifting Russell 1000 Healthcare sentiment. Index/sector recognition can amplify demand for the stock. Kalkine: Beats estimates, lifts Russell 1000 Healthcare</li>
<li>Positive Sentiment: Analyst moves — Several shops nudged targets or reaffirmed ratings (price-target increases to $98 at Citigroup and Wells Fargo; BTIG reiterated a $112 buy target), lending some near-term support. Benzinga: Analyst updates</li>
<li>Neutral Sentiment: Guidance is conservative but roughly in-line — FY2026 EPS guidance was set at $8.30–$8.45 and revenue guidance around $8.4–$8.6B, essentially in line with consensus but underscored by cautious language that tempers upside expectations. MSN: Tops Q4 but measured on 2026 guidance</li>
<li>Neutral Sentiment: U.S. salesforce overhaul — Management flagged a U.S. salesforce restructuring and transition that should improve execution long-term but adds near-term uncertainty and drove a cautious tone on the call. Yahoo Finance: Q4 deep dive — salesforce overhaul</li>
<li>Negative Sentiment: Margins and headwinds — Management acknowledged margin pressure (some contraction noted in the quarter) and called out tariffs and cost dynamics as potential drags on 2026 profit expansion. These factors could limit upside to profitability. Zacks: Q4 earnings &amp; margin commentary</li>
<li>Negative Sentiment: Cautious management tone — While results beat, the measured guidance and commentary imply limited near-term upside and increased execution risk during the transition, which could cap multiple expansion. MSN: Q4 earnings call transcript</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第四季度超预期——ZBH 报告每股收益为 2.42 美元，收入约为 22.4 亿美元（同比增长约 10.9%），超出市场预期，得益于对髋关节和膝关节设备的强劲需求。路透社：Zimmer Biomet 超出季度预期</li>
<li>积极情绪：新回购计划宣布——管理层在业绩公布时推出了一项新的回购计划，支持股价并传达了对现金生成的信心。雅虎财经：ZBH 在业绩超预期和回购后上涨</li>
<li>积极情绪：指数/行业提升——业绩超预期促进了更广泛的医疗行业指数流动，并被认为提升了罗素 1000 医疗行业的情绪。指数/行业认可可以放大对该股票的需求。Kalkine：超出预期，提升罗素 1000 医疗</li>
<li>积极情绪：分析师动态——几家机构调整了目标或重申了评级（花旗和富国银行将目标价格上调至 98 美元；BTIG 重申 112 美元的买入目标），为短期提供了一些支持。Benzinga：分析师更新</li>
<li>中性情绪：指导方针保守但大致符合——2026 财年每股收益指导设定在 8.30–8.45 美元，收入指导在 84 亿–86 亿美元，基本符合市场预期，但用谨慎的语言强调了限制上行预期的因素。MSN：第四季度超出预期，但对 2026 年的指导持谨慎态度</li>
<li>中性情绪：美国销售团队重组——管理层指出美国销售团队的重组和过渡，预计将改善长期执行，但增加了短期不确定性，并在电话会议上传达了谨慎的语气。雅虎财经：第四季度深度分析——销售团队重组</li>
<li>消极情绪：利润率和阻力——管理层承认利润率压力（本季度出现了一些收缩），并指出关税和成本动态可能对 2026 年的利润扩张造成拖累。这些因素可能限制盈利能力的上行。Zacks：第四季度收益与利润率评论</li>
<li>消极情绪：管理层语气谨慎——尽管业绩超出预期，但谨慎的指导和评论暗示短期内上行空间有限，并在过渡期间增加了执行风险，这可能限制市盈率的扩张。MSN：第四季度收益电话会议记录</li>
</ul>
</div><h2>Zimmer Biomet Price Performance</h2>
<div class="lb-trans"><h2>Zimmer Biomet 价格表现</h2>
</div><ul>
<li>2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家机器人手术公司挑战直觉外科的领先地位</li>
</ul>
</div><p>ZBH stock opened at $95.51 on Thursday. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44. The firm has a market capitalization of $18.93 billion, a P/E ratio of 26.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.62. The company has a fifty day simple moving average of $90.01 and a two-hundred day simple moving average of $95.64. The company has a quick ratio of 1.39, a current ratio of 1.98 and a debt-to-equity ratio of 0.55.</p>
<div class="lb-trans"><p>ZBH 股票周四开盘价为 95.51 美元。Zimmer Biomet Holdings, Inc.的 52 周低点为 84.59 美元，52 周高点为 114.44 美元。该公司的市值为 189.3 亿美元，市盈率为 26.98，市盈率增长比为 2.34，贝塔值为 0.62。该公司的 50 日简单移动平均为 90.01 美元，200 日简单移动平均为 95.64 美元。该公司的速动比率为 1.39，流动比率为 1.98，债务与股本比率为 0.55。</p>
</div><p>Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion for the quarter, compared to analysts' expectations of $2.22 billion. During the same period in the prior year, the company earned $2.31 EPS. The business's revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Zimmer Biomet (NYSE:ZBH - 获取免费报告) 最近一次公布财报是在 2 月 10 日，星期二。这家医疗设备供应商报告了每股收益（EPS）为 2.42 美元，超出市场普遍预期的 2.38 美元，超出幅度为 0.04 美元。Zimmer Biomet 的净利润率为 8.56%，股本回报率为 12.93%。该公司本季度的收入为 22.4 亿美元，而分析师预期为 22.2 亿美元。在去年同期，该公司的每股收益为 2.31 美元。与去年同期相比，公司的收入增长了 10.9%。Zimmer Biomet 将其 2026 财年的指引设定为每股收益在 8.300 到 8.450 之间。分析师预计，Zimmer Biomet Holdings, Inc. 在当前财年将公布每股收益为 8.22 美元。</p>
</div><h2>Zimmer Biomet Announces Dividend</h2>
<div class="lb-trans"><h2>Zimmer Biomet 宣布分红</h2>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Zimmer Biomet's dividend payout ratio (DPR) is presently 27.12%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，分红于 1 月 30 日，星期五支付。12 月 30 日的股东获得了 0.24 美元的分红。这相当于年化分红为 0.96 美元，分红收益率为 1.0%。该分红的除息日为 12 月 30 日。Zimmer Biomet 的分红支付比率（DPR）目前为 27.12%。</p>
</div><h2>Zimmer Biomet Company Profile</h2>
<div class="lb-trans"><h2>Zimmer Biomet 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.</p>
<div class="lb-trans"><p>Zimmer Biomet NYSE: ZBH 是一家全球医疗设备公司，专注于肌肉骨骼健康护理。公司总部位于印第安纳州的华沙，设计、制造和销售广泛的产品组合，用于治疗关节疾病、骨骼疾病及相关病症。其客户包括依赖于植入物、仪器和相关服务进行重建和修复手术的骨科和牙科外科医生、医院、门诊手术中心及其他医疗服务提供者。</p>
</div><p>The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.</p>
<div class="lb-trans"><p>公司的产品涵盖髋关节、膝关节和肩关节的关节置换系统；创伤和四肢植入物；脊柱和胸部解决方案；牙科和颅面植入物及假体；以及运动医学设备。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Zimmer Biomet</li>
<li>Is THIS the Next Big Money Rush?</li>
<li>Wall Street Legend Names #1 Stock of 2026 Live On-Camera</li>
<li>ISPC: From Small Cap to Life Sciences Market Disruptor!</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
<li>Is Elon Preparing for a Silver Shock?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Zimmer Biomet</li>
<li>这是下一个大钱潮吗？</li>
<li>华尔街传奇在镜头前命名 2026 年第一只股票</li>
<li>ISPC：从小型股到生命科学市场颠覆者！</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
<li>埃隆是否在为银色冲击做准备？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ZBH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Zimmer Biomet Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Zimmer Biomet 吗？</h2>
</div><p>Before you consider Zimmer Biomet, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Zimmer Biomet 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Zimmer Biomet 并不在名单上。</p>
</div><p>While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Zimmer Biomet 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Johnson Investment Counsel Inc. 减持了 Zimmer Biomet Holdings, Inc. $ZBH 的股票